1. Scrip
  2. >>Business
  3. >>Strategy

R&D Heads At GSK & AZ Say Key To Success Lies In Smart Risk Taking

 
• By Sten Stovall

AZ's Mene Pangalos and GSK's Hal Barron are at different stages of overseeing culture changes in their respective R&D workforces - but both agreed at a recent conference that such transformations are key for the future viability of their drug companies.

SWOT
Pair Say R&D needs better decision-making and focused risk-taking • Source: Shutterstock

The raison d'être of any R&D chief is finding a way to increase the successful translation of innovation into a rejuvenated pipeline and successful new drug launches. The R&D heads of Britain's two biggest pharma companies were asked at a recent London conference what they believe the secret in doing that is – and both agreed that in large part it lies in creating a smarter, more focused risk-taking culture within their teams.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

AstraZeneca COPD Drug Breztri Breezes Through Asthma Trials

 
• By Kevin Grogan

The triple therapy improves lung function in the Phase III KALOS and LOGOS studies

Transient FY26 For Syngene But Momentum In China +1 Projects

 
• By Anju Ghangurde

As biopharma derisks its business with China ‘rebalancing’ strategies, Syngene could convert majority of such pilots into full program contracts amid a challenging FY2025. The CRDMO also expects business discussions pertaining to a newly acquired US biologics site to mature into commercial opportunities.

Biogen’s Manufacturing Sites, Revenue Sources Protect It From Big Tariff Impact

 
• By Mandy Jackson

Biogen expects little impact from existing tariffs and any that may apply if the US exemption of pharma products is lifted, since 75% of its manufacturing is in the US and 55% of sales are ex-US.